当前位置：
X-MOL 学术
›
N. Engl. J. Med.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
The New England Journal of Medicine ( IF 96.2 ) Pub Date : 2017-06-06 , DOI: 10.1056/nejmoa1704795 Solange Peters , D. Ross Camidge , Alice T. Shaw , Shirish Gadgeel , Jin S. Ahn , Dong-Wan Kim , Sai-Hong I. Ou , Maurice Pérol , Rafal Dziadziuszko , Rafael Rosell , Ali Zeaiter , Emmanuel Mitry , Sophie Golding , Bogdana Balas , Johannes Noe , Peter N. Morcos , Tony Mok
The New England Journal of Medicine ( IF 96.2 ) Pub Date : 2017-06-06 , DOI: 10.1056/nejmoa1704795 Solange Peters , D. Ross Camidge , Alice T. Shaw , Shirish Gadgeel , Jin S. Ahn , Dong-Wan Kim , Sai-Hong I. Ou , Maurice Pérol , Rafal Dziadziuszko , Rafael Rosell , Ali Zeaiter , Emmanuel Mitry , Sophie Golding , Bogdana Balas , Johannes Noe , Peter N. Morcos , Tony Mok
|
As compared with crizotinib, alectinib showed superior efficacy and lower toxicity in primary treatment of ALK-positive NSCLC. (Funded by F. Hoffmann–La Roche; ALEX ClinicalTrials.gov number, NCT02075840.)
中文翻译：
艾乐替尼与克唑替尼治疗未治疗的ALK阳性非小细胞肺癌
与克唑替尼相比，艾乐替尼在ALK阳性NSCLC的初级治疗中显示出更高的疗效和更低的毒性。（由F. Hoffmann–La Roche资助； ALEX ClinicalTrials.gov编号，NCT02075840。）
更新日期：2017-08-31
中文翻译：
艾乐替尼与克唑替尼治疗未治疗的ALK阳性非小细胞肺癌
与克唑替尼相比，艾乐替尼在ALK阳性NSCLC的初级治疗中显示出更高的疗效和更低的毒性。（由F. Hoffmann–La Roche资助； ALEX ClinicalTrials.gov编号，NCT02075840。）
京公网安备 11010802027423号